| 摘要 |
<p>The invention relates to methods that can detect the abnormal function of the N-methyl-D-aspartate (NMD A) receptor, which can ascertain whether an individual has vulnerability for schizophrenia or depression. The invention relates to measuring blood plasma osmolality and the concentration of least one biomarker in conjunction with hypertonic solution infusion as a method for detecting or diagnosing schizophrenia or depression. The invention further relates to using arginine-vasopressin (A VP), neurophysin II, and copeptin as biomarkers in a method for detecting or diagnosing schizophrenia or depression.</p> |
